ArticleHIV research & clinical practice2021
Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
Open access · greenAbstract read
In one paragraph
Article in HIV research & clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- The Importance of Social Engagement in the Development of an HIV Cure: A Systematic Review of Stakeholder Perspectives.AIDS and behavior · 2023Pooled it
- Ethical Aspects of Personalized Research and Management of Systemic Inflammatory Response Syndrome (SIRS) in Children.International journal of environmental research and public health · 2022Pooled it
- Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause in the United States: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.AIDS research and human retroviruses · 2022Trial
- Stress and Coping During an HIV Cure-Related Trial with an Analytical Treatment Interruption: A Qualitative Assessment of the Experiences of Young Women in Durban, South Africa.Journal of the International Association of Providers of AIDS CareTrial
- Perspectives on Analytical Treatment Interruptions and Prospects of an HIV Cure Amongst People Living with HIV and Healthcare Providers in Singapore.AIDS and behavior · 2026Article
- Impact of analytical treatment interruptions on sexual behaviors: a mixed-methods longitudinal study of women enrolled in an HIV cure-related trial in Durban, South Africa.HIV research & clinical practice · 2025Article
- 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.HIV research & clinical practice · 2025Article
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- Development and Evaluation of Decision Partner: A Decision Aid for HIV Remission Clinical Trial Participation.AIDS and behavior · 2025Article
- "Sometimes They Exclude Us because of Our Age-That's Not Right": Perceptions of HIV Cure Research Among Diverse Long-Term Survivors in the United States.AIDS research and human retroviruses · 2025Article
- Lessons Learned in Eliciting Systematic Participant Perspectives in a Combination HIV Cure Research Trial.AIDS research and human retroviruses · 2025Article
- Impact of an analytical treatment interruption on partners and family members of trial participants in Durban, South Africa: a qualitative study.Frontiers in public health · 2025Article
- Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk.Journal of virus eradication · 2024Article
- "This Is Actually a Really Unique Moment in Time": Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions-A Qualitative Interview Study in the United States.AIDS research and human retroviruses · 2024Article
- Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.HIV research & clinical practice · 2024Article
- Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.HIV research & clinical practice · 2023Article
- A partner protection package for HIV cure-related trials involving analytical treatment interruptions.The Lancet. Infectious diseases · 2023Review
- 'With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study.HIV research & clinical practice · 2023Article
- Community HIV clinicians' perceptions about HIV cure-related research in the Northwestern United States.HIV research & clinical practice · 2022Article
- "It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States.BMC public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Karine DubéGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-3458-1539
John KanazawaGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lynda DeeAIDS Action Baltimore, Baltimore, MD, USA.
Jeff TaylorDelaney AIDS Research Enterprise (DARE) CAB, San Francisco, CA, USA.
Danielle M CampbellDelaney AIDS Research Enterprise (DARE) CAB, San Francisco, CA, USA.
Brandon BrownDepartment of Social Medicine, Population and Public Health, Center for Healthy Communities, University of California, Riverside, Riverside, CA, USA.ORCID 0000-0002-6348-4108
Mallory O JohnsonCenter for AIDS Prevention Studies (CAPS), Division of Prevention Sciences, UCSF, San Francisco, CA, USA.
Parya SaberiCenter for AIDS Prevention Studies (CAPS), Division of Prevention Sciences, UCSF, San Francisco, CA, USA.
John A SaucedaCenter for AIDS Prevention Studies (CAPS), Division of Prevention Sciences, UCSF, San Francisco, CA, USA.
Jeremy SugarmanJohns Hopkins Berman Institute for Bioethics, Baltimore, MD, USA.
Michael J PelusoDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA, USA.
San Francisco AIDS Foundation · USAdvisory Board Company (United States) · USUniversity of North Carolina at Chapel Hill · USAIDS United · USJohns Hopkins Berman Institute of Bioethics · USUniversity of California, Riverside · USUniversity of California, San Francisco · US
Funding
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MTraining Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MTraining Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4MMentoring and Empowerment in the Context of HIV Care for At-Risk PopulationsK24DA037034 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSON, MALLORY O · 2014 to 2018
$918kPilot Integration of Participant-Centered Outcomes in HIV Cure Research in the United States: Implications for Ethical ConductR21MH118120 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUBE, KARINE · 2019 to 2020
$566kPerceptions of Risks and Benefits of Participating in HIV Cure-related Research among Diverse Youth and Young Adults Living with HIV in the United StatesR21MH122280 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBE, KARINE, SABERI, PARYA · 2020 to 2021
$458kNIAID NIH HHS T32 AI060530NIAID NIH HHS UM1 AI126620NIDA NIH HHS K24 DA037034NIDA NIH HHS T32 DA023356NIMH NIH HHS P30 MH062246NIMH NIH HHS R21 MH118120NIMH NIH HHS R21 MH122280NIMH NIH HHS R25 MH067127
Abstract
background
objective
methods
results
conclusion
Indexed as
HIV InfectionsSexually Transmitted DiseasesHumansResearch PersonnelSexual PartnersViremiaanalytical treatment interruptionsHIVHIV cure researchpartner protectionpeople living with HIVrisk mitigation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.